Doctors are wary of prescribing Lotronex as a therapy for irritable bowel syndrome (IBS) despite the drug’s significant advantages over current and emerging therapies, a new report has found.

The report by Decision Resources shows that doctors are reluctant to prescribe Lotronex because of side effects linked to constipation, which in rare cases have led to blood transfusion, hospitalisation, surgery and even death.

Surveyed primary care physicians said that the therapy’s effect on overall IBS symptoms is the attribute that most influences their prescribing decisions in non-constipation predominant IBS.

The report also identifies Tioga / Ono’s asimadoline as the leading non-constipation predominant irritable bowel syndrome treatment, following the launch of asimadoline in 2013.

Lotronex is indicated for women with severe IBS, whose main problem is diarrhoea and who have not been helped by other treatments.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.